Part 2 of Drug Dyslipdemia Flashcards

1
Q

Atorvastatin
What is the half-life of atorvastatin and how does it affect cholesterol synthesis?

A

A: Atorvastatin has a long half-life, and cholesterol synthesis is suppressed for 24 hours after taking the drug.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Are clinically relevant drug interactions common with atorvastatin?

A

Clinically relevant drug interactions with atorvastatin are less common and problematic compared to other statins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why is atorvastatin considered the drug of choice for patients on protease inhibitors?

A

Atorvastatin is the drug of choice for patients on protease inhibitors because it has fewer clinically relevant drug interactions, making it safer and more effective for these patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Fibrates

A
  • Bezafibrate* (Bezalip®) * Fenofibrate
  • Gemfibrozi
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fibrates: mechanism of action

A

PPARα (peroxisome proliferator-activated receptor α) agonists:
increase transcription for genes for lipoprotein lipase, ApoproteinA1
and ApoproteinA5
* Stimulate the β-oxidative degradation of fatty acids →enhance lipoprotein
lipase ↑ hydrolysis of TG in chylomicrons and VLDL parƟcles → liberate FFAs
for storage in fat or for metabolism in striated muscle, increase hepatic LDL
uptake
* ↓ hepaƟc VLDL producƟon & ↑hepaƟc LDL uptake
* ↓plasma CRP and fibrinogen levels, * improve glucose tolerance, * ↓ vascular smooth muscle inflammaƟon (inhibiƟng expression of
transcription factor nuclear factor KappaB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fibrates: adverse effects

A
  • Common: GI, pruritis and rash
  • Unusual but severe: rhabdomyolysis cause renal failure (excretion of
    muscle proteins (myoglobin)) * More common in patients with renal impairment, because of reduced protein
    binding and impaired drug elimination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fibrates: cautions and contraindication

A

Cautions: * Gall stones and gall bladder disorders
* PUD
* Hyperthyroidism
* Hypoalbuminaemic states (95% protein binding) * Cardiovascular disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what to avoid when taking Fibrates

A

Avoid in patients with renal impairment and alcoholics – predisposed to hypertriglyceridaemia, at risk for severe muscle inflammation and injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Contraindicated:

A
  • Severe renal and hepatic failure
  • Primary biliary cirrhosis
  • Pregnancy and lactation
    Fibrates: cautions and contraindications
    Rang and Dale’s pharmaco
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bezafibrate

A

Bezafibrate is a lipid-lowering drug that belongs to the class of fibrates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the mechanism of action of Bezafibrate?

A

Bezafibrate stimulates the β-oxidative degradation of fatty acids, enhances lipoprotein lipase activity to increase hydrolysis of triglycerides in chylomicrons and VLDL particles, liberates free fatty acids for storage in fat or for metabolism in striated muscle, decreases hepatic VLDL production, and increases hepatic LDl uptake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does Bezafibrate work

A

Pharmacokinetics: 94% excreted in the kidneys (40% unchanged) * Take after meals
* Drug interactions: * Warfarin – increased anticoagulant effect, reduce warfarin dose by half, then
adjust dose according to INR
* Statins – increased risk of rhabdomyolysis
* Sulphonylureas – increased risk of hypogly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is a bile acid binding resin?

A

Bile acid binding resins are a type of medication used to lower cholesterol levels in the blood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do bile acid binding resins work?

A

Bile acid binding resins work by binding to bile acids in the intestines, preventing them from being reabsorbed into the bloodstream. This forces the liver to use more cholesterol to produce bile acids, leading to a decrease in cholesterol levels in the blood.

Bind to bile acids in the intestine and
prevent reabsorption and enterohepatic
recirculaƟon → ↓absorpƟon of exogenous
cholesterol & ↑ metabolism of exogenous
cholesterol into bile acids by the liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Can bile acid binding resins be used alone or in combination with other medications?

A

Bile acid binding resins can be used alone or in combination with other cholesterol-lowering medications, such as statins, to achieve optimal cholesterol control.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the common side effects of bile acid binding resins?

A

Common side effects of bile acid binding resins may include gastrointestinal issues such as constipation, bloating, gas, and abdominal discomfort. These side effects typically improve over time or with adjustments in dosage.

Not absorbed – systemic toxicity low
* GI symptoms; nausea, abdominal
bloating, constipation, diarrhoea =
common + dose related

17
Q

are there any precautions or contraindications associated with bile acid binding resins?

A

They may also interfere with the absorption of other medications, so it’s important to take them at least one hour before or four hours after other medications.

Interfere with absorption of fatsoluble vitamins and drugs; warfarin,
digoxin, chlrorothiazide – take 1 hour
before or 4-6 hours after * Inconvenient to use

18
Q

Nicotinic acid

A

Nicotinic Acid (Niacin)

Uses: Primarily used to manage cholesterol levels. At lower doses, it can reduce adverse effects (AEs) compared to higher doses.
Effectiveness: Effective in reducing triglycerides (TGs) and low-density lipoprotein (LDL) cholesterol, and in increasing high-density lipoprotein (HDL) cholesterol. The effectiveness in lower doses needs further evaluation.

19
Q

Mechanism of Action (MOA)

A

Hepatic TG Production: Inhibits the production of triglycerides in the liver.
VLDL Secretion: Reduces the secretion of very-low-density lipoprotein (VLDL).
Cholesterol Effects: The reduction in VLDL leads to a decrease in LDL (bad cholesterol) and an increase in HDL (good cholesterol).

20
Q

Adverse Effects (AEs)

A

Normal Doses:
Flushing: Caused by the production of prostaglandin D₂ (PGD₂). This can be mitigated by taking niacin 30 minutes after aspirin.
Palpitations
Gastrointestinal (GI) Disturbances

High Doses:
Liver Function Disorders: High doses can lead to hepatotoxicity.
Impairment of Glucose Tolerance: Can negatively affect blood sugar control.
Precipitation of Gout: High doses can lead to an increase in uric acid levels, potentially precipitating gout.

21
Q

Ezetimibe

A

Uses: Primarily used to lower low-density lipoprotein (LDL) cholesterol. It is often used in combination with statins for enhanced cholesterol-lowering effects.

22
Q

Mechanism of Action (MOA)

A

Inhibition of Cholesterol Absorption: Ezetimibe works by inhibiting the absorption of cholesterol and related plant sterols in the intestine.
Reduction in LDL: This inhibition leads to a reduction in LDL cholesterol levels by approximately 15%.

23
Q

Synergy with Statins

A

Combined Effects:
Decrease in Hepatic Cholesterol: Statins inhibit the de novo synthesis of cholesterol in the liver.
Decrease in Dietary Cholesterol Delivery: Ezetimibe reduces the amount of dietary cholesterol delivered to the liver.
LDL Receptor Upregulation: The combination of these two effects results in a greater upregulation of LDL receptors than with statins alone, leading to more significant reductions in LDL cholesterol.
Combination Therapy
Inegy® (Ezetimibe + Simvastatin): This combination drug leverages the complementary mechanisms of action of ezetimibe and simvastatin to provide a more potent reduction in LDL cholesterol levels

24
Q

adverse effect of Ezitimibe

A

Adverse effects
* Common: * Headache
* Abdominal pain
* Diarrhoea
* Combined with statin: * Constipation, nausea & flatulence
* ↑ ALT/AST
* Myalgia & rhabdomyolysis.

25
Q

Ezetimibe Combined with statin.

A

Constipation, nausea & flatulence
* ↑ ALT/AST
* Myalgia & rhabdomyolysis

26
Q

Contraindications.

A
  • Moderate to severe hepatic
    impairment * Children < 10 years.
27
Q

Cardiovascular risk (scoring)

A
  • Patients at risk for cardiovascular diseases
  • Such as stroke and myocardial infarction
  • May benefit from: * lifestyle modification and * lipid-lowering medicine therapy. * Management should be guided by: * level of risk and lipid lowering medicines shoul
28
Q

what are modifiable risk factors of Cardiovascular risk factors

A

Modifiable
* ↑TG & LDL
* Hypertension / on antihypertensives
* Cigarette smoking (10
cigarretes/day for 10 years) * ↓HDL
* Diabetes
* Obesity (BMI ≥30kg/m² or waist circ >94 men, >80 women) * Physical inactivity

29
Q

the Non-modifiable factors

A
  • Gender * Age
  • Family history of premature CVD (male <55 years, female <60 years) * Autoimmune chronic inflammatory conditions (RA, SLE, psoriasis
30
Q

Cardiovascular risk levels

A
  • Very high risk
  • High risk
  • Risk calculators (determine 10-year risk for CVD): * BMI-based risk assessment * Framingham risk scores (estimates the 10-year risk of manifesting
    clinical CVD)
31
Q

Very high risk

A

Established atherosclerotic disease,* i.e. * Coronary artery disease
* Cerebrovascular disease
* Peripheral arterial disease
* Type 2 diabetes plus one or more other risk factors (smoking,
hypertension, dyslipidaemia) or age >40 years
* Type 1 diabetes with micro-albuminuria or proteinuria
* Genetic dyslipidaemia, e.g. Familial hypercholesterolemia (FH),
dysbetalipoproteinaemia, individuals with total cholesterol (TC) >7.5
mmol/L and/or LDL-C >5 mmol/L
* Severe CKD (GFR <30 mL/min/1.73 m2) * Asymptomatic individua

32
Q
A

Markedly elevated BP (systolic BP ≥180 mmHg and/or
diastolic BP ≥110 mmHg) * Uncomplicated type 1 diabetes and type 2 diabetes aged
<40 years without other risk factors
* Chronic kidney disease (GFR 30 - 59 mL/min/1.73 m2)

33
Q

Cardiovascular risk calculator score

A

Management is based on the patient’s 10-year risk of a
cardiovascular event as follows: * < 10% risk: lifestyle modification and risk assess patient
every 5 years
* 10–20% risk: lifestyle modification and risk assess patient
annually
* ≥ 20% risk: lifestyle modification and start statin treatment